The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma

Future Oncology

Volumn 8, Issue 8, 2012, Pages 1051-1057

  Imarisio, Ilaria ^a   Paglino, Chiara ^a   Ganini, Carlo ^a   Magnani, Luigi ^a   Caccialanza, Riccardo ^a   Porta, Camillo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

diabetes mellitus; hepatocellular carcinoma; metastatic renal cell carcinoma; sorafenib; targeted therapy

Indexed keywords

GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAL PAIN; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BODY MASS; CONFUSION; CONSTIPATION; DECREASED APPETITE; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ERUPTION; DRUG SUBSTITUTION; DYSGEUSIA; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HAND FOOT SYNDROME; HEMORRHOID; HUMAN; HYPERAMMONEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PAIN; PRIORITY JOURNAL; STOMATITIS; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; COMORBIDITY; DIABETES MELLITUS; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PYRIDINES; TREATMENT OUTCOME;

EID: 84865230737     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.74     Document Type: Article

References (35)

1. Simpson D, Keating GM. Sorafenib in hepatocellular carcinoma. Drugs 68(2), 251-258 (2008).
2. McKeage K, Wagstaff AJ. Sorafenib in advanced renal cancer. Drugs 67(3), 475-483 (2007).
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J. Clin. Oncol. 27(20), 3312-3318 (2009).
4. Alves RC, Alves D, Guz B et al. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann. Hepatol. 10(1), 21-27 (2011).
5. Keating G, Santoro A. Sorafenib. A review of its use in advanced hepatocellular carcinoma. Drugs 69(2), 223-240 (2009).
6. Porta C, Bellmunt J, Eisen T et al. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36, 16-23 (2010).
7. Janzen NK, Kim HL, Figlin RA et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. 30, 843-852 (2003).
8. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
9. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious comorbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993-1996. J. Clin. Epidemiol. 52, 1131-1136 (1999).
10. Gernone A, Pagliarulo A, Pagliarulo V. Comorbidity and sorafenib (SOR) therapy in elderly patients with metastatic renal cell carcinoma. J. Clin. Oncol. 29(Suppl. 7), Abstract 398 (2011).
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
12. Consensus Committee. Consensus statement on the worldwide standardization of the haemoglobin A1c measurement: American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 30, 2399-2400 (2007).
13. International Expert Committee. International Expert Committee report on the role of HbA1c assay in the diagnosis of diabetes. Diabetes Care 32, 1327-1334 (2009).
14. WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF Consultation. WHO, Geneva, Switzerland (2006).
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl. 1), S62-S69 (2010).
16. Lindblad P, Chow WH, Chan J et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologica 42(10), 107-112 (1999).
17. Joh HK, Willett WC, Cho E. Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 34(7), 1552-1556 (2011).
18. Davila JA, Morgan RO, Shaib Y et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54, 533-539 (2005).
19. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiological evidence. Clin. Gastroenterol. Hepatol. 4(3), 369-380 (2006).
20. Hassan MM, Curley SA, Li D et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8), 1938-1946 (2010).
21. Valter D, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol. 15(20), 2506-2511 (2009).
22. Lagiou P, Kuper H, Stuver SO et al. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J. Natl Cancer Inst. 92(13), 1096-1099 (2000).
23. Polesel J, Zucchetto A, Montella M et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol. 20, 353-357 (2009).
24. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47(9), 1287-1298 (2011).
25. Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin. Med. Insights Oncol. 4, 143-154 (2010).
26. Billemont B, Medioni J, Taillade L et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 99(9), 1380-1382 (2008).
27. Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Lett. Ann. Oncol. 19(4), 824-825 (2008).
28. Agostino N, Chinchilli VM, Lynch CJ et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J. Oncol. Pharm. Pract. 17(3), 197-202 (2011).
29. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol. 22(8), 1812-1823 (2011).
30. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5), 1272-1280 (2010).
31. Porta C, Paglino C, Imariso I et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 11, 105 (2011).
32. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J. Support. Oncol. 9, 13-23 (2011).
33. Antonelli A, Fallahi P, Ferrari SM et al. New targeted therapies for thyroid cancer. Curr. Genomics 12(8), 626-631 (2011).
34. Gradishar WJ. Sorafenib in locally advanced or metastatic breast cancer. Expert Opin. Investig. Drugs 21(8), 1177-1191 (2012).
35. Posades EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park) 26(3), 290-301 (2012).